RxDoctor Payments Data

Jennifer Unger, MD

Ophthalmology · Oak Creek, WINPI 1598836736

Payments from drug & device makers

What this record shows

20 manufacturers reported payments, led by Nidek CO., LTD. at 45.0% of the total. Reporting peaked in 2022 at $1,959 and has fallen 93.8% since, to $122 in 2023.

$3,334in general payments, 2019–2025

Across 95 payments — averaging $35.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nidek CO., LTD.$2K
  • AbbVie$499
  • Novartis$312
  • Kala Pharmaceuticals, Inc.$226
  • The Cameron-ehlen Group, Inc.$124
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$120
  • plus $552 from 14 others

What the payments were for

  • Speaking & faculty fees$1,50045%
  • Food & beverage$1,83455%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,334 in reported general payments places this provider in the 85th percentile of 337 ophthalmology providers in Wisconsin.

See all ophthalmology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$80,354
Medicare patients
230
Services billed
1,309

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine19$12,652
LumiganBimatoprost11$4,527
Prednisolone Acetate59$2,843
Timolol Maleate39$2,038
Brimonidine Tartrate62$1,615
Latanoprost106$1,401
Ketorolac Tromethamine37$1,028
ErythromycinErythromycin Base63$810
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat34$791
Ofloxacin28$350
Dorzolamide Hcl18$337
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha20$276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$499$17,17930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 337 ophthalmology providers in Wisconsin.

Other ophthalmology in Oak Creek

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →